Welcome to our dedicated page for Benitec Biopharm SEC filings (Ticker: BNTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Benitec Biopharma Inc.’s SEC filings document a Nasdaq-listed clinical-stage biotechnology company developing genetic medicines, including the BB-301 program for OPMD-related dysphagia. Its reports and current filings cover operating and financial results, clinical-development updates, Regulation FD disclosures, and capital-structure information for its common stock.
The company’s proxy and governance filings describe annual meeting matters, board composition, director compensation, equity incentive arrangements, and related corporate-governance disclosures. Form 8-K filings also record material events such as financial-result releases, operational updates, clinical-study disclosures, and director appointments.
Franklin Resources and affiliates have reported a significant ownership position in Benitec Biopharma Inc. They report beneficial ownership of 3,751,709 shares of common stock, representing 10.6% of the company as of 12/31/2025, including 1,554,404 shares issuable upon exercise of warrants.
Franklin Advisers, Inc. holds sole voting and dispositive power over these 3,751,709 shares. Charles B. Johnson and Rupert H. Johnson, Jr. are listed as reporting persons but show no directly beneficially owned shares. A key client, Franklin Biotechnology Discovery Fund, has an interest in 2,445,585 shares, or 6.9% of the class.
The securities are held for investment management clients in the ordinary course of business, and the filers state they were not acquired to change or influence control of Benitec. Franklin Resources, the principal shareholders, and subsidiaries also disclaim being a group or ultimate beneficial owners beyond their investment management role.
Benitec Biopharma Inc. director Sharon Mates received a grant of stock options covering 31,500 shares of common stock. The options were awarded on January 22, 2026 at an exercise price of $12.83 per share, with no cash paid at grant.
These options are held directly and give the right to buy Benitec common stock in the future. According to the terms, the options will vest on the earlier of the company’s next annual stockholders’ meeting or December 1, 2026, tying the award to a medium-term service period on the board.
Benitec Biopharma Inc. (BNTC) reported a new stock option grant to its Chief Operating Officer, Sophie Mukadam, in an ownership filing. On 11/18/2025, she received options to purchase 500,000 shares of Benitec common stock at an exercise price of $13.53 per share, expiring on 11/18/2035. These options are scheduled to vest in 16 substantially equal quarterly installments beginning on March 31, 2026, meaning the award vests gradually over four years while she remains in her role.
Benitec Biopharma Inc. (BNTC) reported an equity award to its Chief Executive Officer and director, Jerel A. Banks, on a Form 4. On November 18, 2025, he received 450,000 stock options with an exercise price of $13.53 per share, giving him the right to buy Benitec common stock at that price.
The options have a long-term horizon, expiring on November 18, 2035. According to the filing, they will vest in 16 substantially equal quarterly installments, beginning on March 31, 2026. After this grant, Jerel A. Banks beneficially owned 450,000 stock options, held directly.
Benitec Biopharma Inc. (BNTC) reported a stock option grant to director and Chief Financial Officer Megan Boston. On 11/18/2025, she received options to purchase 200,000 shares of common stock at an exercise price of $13.53 per share, expiring on 11/18/2035.
The options will vest in 16 substantially equal quarterly installments beginning on March 31, 2026, meaning the award vests gradually over four years. The filing indicates she holds these options directly, reflecting a standard equity-based compensation grant that aligns executive incentives with shareholder interests.
Benitec Biopharma Inc. (BNTC) filed an 8‑K stating it furnished a press release with financial results for the fiscal quarter ended September 30, 2025, and an operational update. The press release is attached as Exhibit 99.1.
The company notes the information furnished under Item 2.02, including Exhibit 99.1, is not deemed filed for liability purposes and is not incorporated by reference unless expressly stated. BNTC’s common stock trades on The Nasdaq Stock Market LLC.
Benitec Biopharma (BNTC) reported quarterly results with no revenue and a net loss of $8.97 million for the three months ended September 30, 2025. Operating expenses were $9.80 million, led by R&D $3.37 million and G&A $6.43 million. Cash used in operating activities was $3.35 million.
The company ended the quarter with $94.5 million in cash and cash equivalents and stated this is sufficient to fund operations for at least the next twelve months from the date of the report. Subsequent to quarter-end, Benitec completed an underwritten offering of 5,930,000 shares at $13.50 and a concurrent registered direct sale of 1,481,481 shares at $13.50, for gross proceeds of approximately $100 million. Shares outstanding were 26,250,469 as of September 30, 2025; 33,862,226 were outstanding as of November 14, 2025. Benitec continues advancing BB-301, its silence-and-replace AAV gene therapy for OPMD, with multiple subjects treated in an ongoing Phase 1b/2a study.
Benitec Biopharma (BNTC) reported insider purchases by joint filers associated with Suvretta Capital. On 11/07/2025, the reporting persons acquired 730,370 shares of common stock at $13.5 per share and separately acquired 751,111 shares at $13.5. The holdings following these transactions were reported as 9,538,175 shares and 1,819,812 shares, respectively. The positions are listed as indirect ownership, and the filers are identified as a Director and 10% Owner. Additional explanatory notes are referenced in Exhibit 99.1.
Benitec Biopharma (BNTC) reported an insider equity award. A director received options to purchase 28,517 shares on 11/05/2025 at an exercise price of $15.78 per share. These options were granted for $0 and expire on 11/05/2035. The award will vest in full on the earlier of immediately prior to the company’s 2026 annual meeting of stockholders or November 5, 2026. Following the grant, the director holds 28,517 derivative securities directly.
Benitec Biopharma Inc. (BNTC) reported an insider ownership update. A director filed a Form 3 initial statement of beneficial ownership under Section 16. The filing states that no securities are beneficially owned.
The event date is 11/03/2025, and the form was signed by Sharon Mates on 11/07/2025. This is an administrative disclosure of initial insider status and holdings.